Antigen-Presenting Cell Electroporation for T-Cell Stimulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods using antigen-presenting cells (APCs) loaded with target-specific antigens are insufficient in eliciting a strong immune response due to complex manipulation processes that alter their properties and fail to express necessary cellular markers, leading to T-cell tolerance.
Innovation Solution
Enhancing the T-cell stimulatory capacity of APCs by electroporating them with a mixture of mRNA or DNA molecules encoding immunostimulatory factors such as CD40L, CD70, caTLR4, IL-12p70, and others, which also includes the use of molecular adjuvants like CD40L and CD70 to overcome T-cell tolerance and improve immunostimulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antigen presenting cells are manipulated in vitro to load with target-specific antigens, then they can present antigens to T-cells, but their characteristic properties such as cytokine secretion are lost
Solution Approach 1:
The patent divides the complex manipulation process into separate steps: first loading APCs with target-specific antigens, then separately adding molecular adjuvants (CD40L, CD70, caTLR4) to restore immunostimulatory properties. This segmentation allows each function to be optimized independently without interfering with the other.
Solution Approach 2:
The patent changes the functional parameters of APCs by introducing specific molecules (CD40L, CD70, caTLR4) that modify the cells' immunostimulatory capacity. These parameter changes restore and enhance cytokine secretion and T-cell activation abilities that were lost during antigen loading.
2Reliability
If antigen presenting cells are artificially modified to present target-specific antigens, then they can overcome T-cell tolerance, but they fail to express necessary cellular markers on their cell surface
Solution Approach 1:
The patent applies preliminary action by pre-modifying APCs with molecular adjuvants (CD40L, CD70, caTLR4) before antigen presentation. This preliminary modification ensures that necessary cellular markers are expressed and immunostimulatory properties are established before the APCs encounter T-cells, enabling them to effectively overcome T-cell tolerance.
Solution Approach 2:
The patent creates a composite functional structure on APCs by combining target-specific antigens with molecular adjuvants (CD40L, CD70, caTLR4). This composite approach ensures both antigen presentation capability and proper cellular marker expression coexist on the same cell surface.
3Reliability
If complex manipulation processes are used to load APCs with antigens, then antigen presentation is achieved, but the process becomes complicated and alters APC properties
Solution Approach 1:
The patent extracts the essential immunostimulatory functions (cytokine secretion, cellular marker expression) from the complex manipulation process and restores them through direct addition of molecular adjuvants (CD40L, CD70, caTLR4). This simplifies the overall process by separating antigen loading from immunostimulatory property restoration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach significantly enhances the immunostimulatory characteristics of APCs, enabling them to stimulate antigen-specific T-cells both in vitro and in vivo, forming a promising method for immunotherapy against cancer, viral, bacterial, and fungal infections.
Implementation Method 1
The inventors have established that the T cell stimulatory capacity of antigenic-peptide pulsed antigen presenting cells or antigen presenting cells (co-)electroporated with an mRNA encoding a target-specific antigen can be greatly enhanced by providing them with three different molecular adjuvants through electroporation with a mixture of mRNA or DNA molecules encoding two or more immunostimulatory factors.
Data Source
AI summary
With the current invention, we provide new methods of enhancing the T-cell stimulatory capacity of human dendritic cells (DCs) and their use in cancer vaccination. The method comprises the introduction of different molecular adjuvants to human DCs through transfection with at least two mRNA or DNA molecules encoding markers selected from the group of: CD40L, CD70, constitutively active TLR4 (caTLR4), IL-12p70, EL-selectin, CCR7 and/or 4-1 BBL; or in combination with inhibition of SOCS, A20, PD-L1 and/or STAT3 expression, for example through siRNA transfection. We could show a clear increase in the immunostimulatory capacity of DCs obtained in this way, enabling them to elicit an unexpectedly high T-cell immune response in vitro. Introduction of at least two of the above molecules, in combination with a tumor-specific antigen enables the DCs to elicit a significant host-mediated T-cell immune response in vivo against the tumor antigen and thus makes them very attractive in the manufacturing of anti-cancer vaccines.